Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.
Andrew S. Chi, MD, PhD
Advertisement
Articles by Andrew S. Chi, MD, PhD
Advertisement
Latest Updated Articles
NYU Scientist Sees Hope Peeking Through Gloom of GlioblastomaPublished: October 4th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5